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affected during this epidemic. Fourteen patients died; these 
deaths occurred in Kathmandu, the capital of Nepal, or in 
different cities in India after these patients were transferred 
there for better treatment. Fifty pregnant women had acute 
jaundice, but none of these women died.
The epidemic was presumed to be caused by consump-
tion of contaminated water (3). In February and March 2014, 
water and sewerage pipelines were damaged in different ar-
eas of Biratnagar during construction and repair of roads. A 
survey conducted by the Department of Community Medi-
cine, B.P. Koirala Institute of Health (Dharan, Nepal), found 
high levels of coliform bacteria in water supplies from differ-
ent areas in Biratnagar during the epidemic. Tap water also 
looked cloudy and visibly contaminated (3).
To obtain more information about the epidemic, the 
incidence of acute jaundice was determined for 656 pris-
oners and 75 security personnel at the Biratnagar Jail. The 
study protocol was approved by the Liver Foundation Ne-
pal. Informed consent was not obtained because identity of 
patient samples remained anonymous. Acute jaundice was 
detected among 30 (4.6%) prisoners and 4 (5.3%) security 
personnel. The same source of consumable water was used 
by the general population, inmates, and security personnel 
in Biratnagar.
To identify the causative agent of this epidemic, se-
rum samples from 48 patients were obtained at Koshi Zon-
al Hospital, the largest government hospital in this zone. 
Hepatitis A virus RNA and IgM against hepatitis B virus 
core antigen was not detected in the 48 serum samples. 
Conversely, IgG, IgM, and IgA against HEV were detected 
in 47 (97.9%), 45 (94%), and 45 (94%) serum samples, re-
spectively, and HEV RNA was detected in 42 (87.5%) of 
48 serum samples, which indicated that the epidemic was 
caused by HEV.
A partial 412-nt sequence from open reading frame 2 
corresponding to nt 5944–6355 of the HEV B1 genome (4) 
was obtained as reported (5). We obtained 40 HEV isolates 
from the 42 samples and sequenced partial 412-nt seg-
ments. All 40 HEV sequences from the epidemic in Birat-
nagar segregated into a cluster within genotype 1a (Figure). 
These sequences showed 99.8% nt identity with each other 
but only 90.8%–95.4% nt identity with other HEV isolates 
from Nepal and those from India, Bangladesh, Pakistan, 
and China.
Compared with previous HEV epidemics in Nepal (6) 
and other parts of the Indian subcontinent, the local govern-
ment of Biratnagar and central government of Nepal took 
steps to contain the reported epidemic. Activities of public 
and private sectors in Biratnagar ended the epidemic in ≈12 
weeks, and no new cases of acute jaundice have been re-
ported in Biratnagar.
Persons in Biratnagar were given information re-
garding epidemics and ways to contain them. They were 
instructed by electronic media to use boiled water for 
consumption. It became clear that additional information 
regarding about maintaining water and sewerage systems 
during road construction and repair should also be provid-
ed. Because 14 patients died of HEV infection during this 
epidemic, more preparedness for epidemics of waterborne 
diseases is required to minimize unnecessary illnesses 
and deaths.
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To the Editor: Human parvovirus 4 (PARV4) is a 
single-stranded DNA virus in the family Parvoviridae (1). 
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In Western countries, IgG against PARV4 is largely found 
only in persons with risk factors for parenteral infection and 
is strongly associated with co-infection with bloodborne vi-
ruses (2–4). In Africa, transmission seems to be more com-
plicated; reported PARV4 seroprevalence is 4%–37%, even 
among persons at low risk and with no evidence of HIV or 
hepatitis C virus (HCV) co-infection (1,5,6).
The clinical significance of PARV4 infection remains 
uncertain. Infections may be asymptomatic, but a variety of 
clinical associations have been reported (1,7), including an 
increased rate of progression to AIDS in persons co-infect-
ed with HIV (8). This association raises particular concerns 
for many African populations in which these viruses are 
co-endemic.
To characterize the epidemiology of PARV4 infection 
in South Africa, we studied adults and children from pedi-
atric outpatient clinics in Kimberley, South Africa, during 
May 2009–August 2013. Of the 157 participants, 90 were 
HIV-1–infected children, 24 their HIV-negative siblings, 
and 43 HIV-1–infected mothers (of whom 4 had >1 child 
enrolled). Approval was given by the Ethics Committee 
of the Faculty of Health Science, University of Free State, 
South Africa. Written consent was given by all adults and 
parents/guardians on behalf of their children.
Blood samples were collected from participants, and 
serum was tested for evidence of PARV4 infection by us-
ing ELISA (in duplicate) to detect IgG against PARV4 viral 
protein 2 (3,6) and by using PCR to detect PARV4 DNA 
(9). For 92 patients, HIV RNA loads were available; testing 
was performed by using the Abbott Laboratories m2000 
platform (Abbott Park, IL, USA). For 118 of the HIV-in-
fected patients, CD4+ T-cell counts were ascertained by 
flow cytometry. Statistical analyses were undertaken by 
using Prism version 6.0f and online software (http://graph-
pad.com/quickcalcs/). Confidence intervals were calculated 
by using the adjusted Wald method (http://www.measuring 
usability.com/wald.htm).
We detected IgG against PARV4 in 58 (37%) of 157 
patients; this proportion is broadly comparable with that re-
ported from other settings in sub-Saharan Africa, including 
Burkina Faso, the Democratic Republic of the Congo, and 
a previous cohort of HIV-infected persons in South Africa 
(5). Although routes of transmission in Africa remain to be 
characterized, these high seroprevalence rates support the 
possibility that some PARV4 transmission may be occur-
ring by nonparenteral routes, as suggested by others (5,10).
PARV4 IgG seroprevalence was higher among adults 
(49%) than children (33%), although this difference did not 
reach statistical significance (p = 0.07, Fisher exact test; 
Figure, panel A). We found a significant relationship be-
tween increasing age and PARV4 IgG serostatus (R2 = 0.59 
by linear regression, p = 0.025; Figure, panel B). The num-
bers in each group are small, and further work is needed to 
define this association with more confidence. We did not 
detect any cases of PARV4 viremia, suggesting that chron-
ic viremia or reactivation are probably uncommon, even 
among HIV-infected patients.
On the basis of previously reported data demonstrat-
ing PARV4 viremia in neonates (7), we hypothesized that 
vertical transmission is possible. To investigate further, we 
sought evidence of concordance between IgG serostatus of 
mothers and their children. Maternal PARV4 IgG status did 
not differ between IgG-positive and IgG-negative children (p 
= 1.00, Fisher exact test; online Technical Appendix Table 1, 
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Figure. Relationship between age and seroprevalence of IgG 
against human parvovirus 4 (PARV4) among 157 mothers and 
children in Kimberley, South Africa, 2009–2013. A) Number and 
proportion of children and adults seropositive for IgG against 
PARV4; the number in each group is shown above the bar. p 
value calculated by using the Fisher exact test. B) Proportion 
of population seropositive for IgG against PARV4 according to 
age; the number in each group is shown above the bar. Data are 
shown for 143 persons because no date of birth was recorded for 
2 children and 12 adults. Error bars show 95% CIs calculated by 
the adjusted Wald method. R2 was calculated by linear regression 
(dotted line). We considered whether maternal antibodies might 
be contributing to PARV4 IgG seroprevalence among those 0–4 
years of age. However, from 11 children in this group who were 
<12 months of age (in whom detection of maternal antibody might 
still be expected), 2 were PARV4 IgG seropositive, and only 1 
of these had an IgG-positive mother, suggesting that maternal 
antibodies did not contribute significantly to PARV4 seropositivity 
in this cohort.
http://wwwnc.cdc.gov/EID/article/21/4/14-1545-Techapp1.
pdf). The absence of correlation between the IgG statuses of 
mothers and children suggests that vertical transmission is 
probably not a major contributor to new infections, although 
it remains plausible that it may sometimes occur.
Data from Europe that suggest an association between 
PARV4 infection and progression to Centers for Disease 
Control and Prevention B-syndromes in HIV-positive per-
sons are problematic because of confounding high rates of 
HCV infection and injection drug use in the PARV4-pos-
itive group (8). We sought evidence for this effect in our 
cohort, in which rates of HCV infection and injection drug 
use were likely to be negligible. We found no evidence of 
a PARV4 serostatus effect on HIV RNA load or CD4+ T 
cells in children (p = 0.13, p = 0.68, respectively; online 
Technical Appendix Table 1) or adults (p = 0.15, p = 0.77, 
respectively; online Technical Appendix Table 2).
We found an unexpected negative correlation between 
PARV4 IgG and HIV status in children (p = 0.05, Fisher 
exact test; online Technical Appendix Table 1). One possi-
ble explanation is that a detectable PARV4 IgG response is 
not mounted or maintained in the context of HIV infection; 
however, this theory is not supported by previous studies 
in which PARV4 IgG seems to be more prevalent in HIV-
infected populations (5,8).
Our analysis was limited by small numbers tested and 
the retrospective approach to sample testing. Demographic 
data were not recorded for this cohort, so we are unable to 
explore further possible social or demographic risk factors 
that might correlate with PARV4 infection.
This study contributes to an evolving body of data sug-
gesting that PARV4 is highly endemic to different settings 
across Africa. The unknown clinical effects and transmis-
sion routes of this virus remain pressing questions for fu-
ture research.
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